Anna Angona

1.8k total citations
34 papers, 650 citations indexed

About

Anna Angona is a scholar working on Genetics, Molecular Biology and Hematology. According to data from OpenAlex, Anna Angona has authored 34 papers receiving a total of 650 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 19 papers in Molecular Biology and 19 papers in Hematology. Recurrent topics in Anna Angona's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (28 papers), Kruppel-like factors research (19 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Anna Angona is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (28 papers), Kruppel-like factors research (19 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Anna Angona collaborates with scholars based in Spain, Czechia and Austria. Anna Angona's co-authors include Alberto Álvarez‐Larrán, Beatríz Bellosillo, Carles Besses, Luz Martínez‐Avilés, Juan Carlos Hernández‐Boluda, Montse Gómez, Águeda Ancochea, Carlos Besses, Alicia Senín and Francesc García‐Pallarols and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Anna Angona

30 papers receiving 640 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Angona Spain	14	563	380	339	270	31	34	650
Luz Martínez‐Avilés Spain	13	429 0.8×	279 0.7×	329 1.0×	176 0.7×	36 1.2×	26	619
Paul Revell United Kingdom	3	624 1.1×	374 1.0×	376 1.1×	236 0.9×	130 4.2×	5	776
P. Gopalakrishna United States	5	476 0.8×	381 1.0×	268 0.8×	179 0.7×	20 0.6×	7	616
Jean‐Loup Demory France	8	570 1.0×	491 1.3×	269 0.8×	175 0.6×	9 0.3×	14	641
Fabrizio Ciccone Italy	8	403 0.7×	460 1.2×	57 0.2×	208 0.8×	112 3.6×	13	574
Julian Perez Ronco Switzerland	7	278 0.5×	211 0.6×	156 0.5×	130 0.5×	29 0.9×	15	373
Mark Wildgust United States	8	352 0.6×	350 0.9×	54 0.2×	179 0.7×	156 5.0×	19	588
Kris Gillis Belgium	11	200 0.4×	237 0.6×	58 0.2×	134 0.5×	20 0.6×	26	539
J. Janssen Netherlands	9	222 0.4×	285 0.8×	75 0.2×	111 0.4×	47 1.5×	11	412
А К Голенков Russia	7	239 0.4×	369 1.0×	127 0.4×	185 0.7×	24 0.8×	16	451

Countries citing papers authored by Anna Angona

Since Specialization

Citations

This map shows the geographic impact of Anna Angona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Angona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Angona more than expected).

Fields of papers citing papers by Anna Angona

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Angona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Angona. The network helps show where Anna Angona may publish in the future.

Co-authorship network of co-authors of Anna Angona

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Angona. A scholar is included among the top collaborators of Anna Angona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Angona. Anna Angona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mora, Elvira, Natalia de las Heras, Anna Angona, et al.. (2024). Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib. Annals of Hematology. 103(11). 4537–4544. 1 indexed citations

Mora, Elvira, Natalia de las Heras, Anna Angona, et al.. (2023). Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study. Blood. 142(Supplement 1). 3177–3177.

Hernández‐Boluda, Juan Carlos, Alberto Álvarez‐Larrán, José María Raya, et al.. (2022). Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers. 14(9). 2331–2331. 3 indexed citations

Marcé, Sílvia, Blanca Xicoy, Olga García, et al.. (2021). Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. Journal of Clinical Medicine. 10(14). 3146–3146. 11 indexed citations

Fernández‐Rodríguez, Concepción, Anna Angona, Leonor Arenillas, et al.. (2021). Clonal Dynamics of JAK2V617F and Non-Driver Mutations in Polycythemia Vera and Essential Thrombocythemia Patients Receiving Hydroxyurea Therapy. Blood. 138(Supplement 1). 3623–3623. 1 indexed citations

Réa, Delphine, Sławomira Kyrcz‐Krzemień, Paolo Sportoletti, et al.. (2021). Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results. Blood. 138(Supplement 1). 635–635. 3 indexed citations

Salar, Antonio, Eugènia Abella, Esteban Jódar Gimeno, et al.. (2019). PB1685 RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA MIMICKING MIKULICZ SYNDROME DURING BLINATUMUMAB TREATMENT: A CASE REPORT. HemaSphere. 3(S1). 776–777.

Arenillas, Leonor, Lourdes Florensa, Anna Puiggros, et al.. (2018). Diagnostic Utility of Flow Cytometric Immunophenotyping in Chronic Myelomonocytic Leukemia. Blood. 132(Supplement 1). 5526–5526. 1 indexed citations

Senín, Alicia, Concepción Fernández‐Rodríguez, Beatríz Bellosillo, et al.. (2017). Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Annals of Hematology. 97(3). 443–451. 35 indexed citations

10.

Angona, Anna, Alberto Álvarez‐Larrán, Beatríz Bellosillo, et al.. (2016). Characterization of CD34+ hematopoietic progenitor cells in JAK2 V617F and CALR -mutated myeloproliferative neoplasms. Leukemia Research. 48. 11–15. 6 indexed citations

11.

Fernández, Concepción, Raquel Longarón, Silvia Pairet, et al.. (2015). Molecular charcterization of myeloproliferative neoplasms evolved to acute myeloid leukemia. Clinical Lymphoma Myeloma & Leukemia. 15. S16–S17. 2 indexed citations

12.

Angona, Anna, Alberto Álvarez‐Larrán, Beatríz Bellosillo, et al.. (2014). Trombocitemia esencial: características iniciales y factores de riesgo de supervivencia y trombosis en una serie de 214 pacientes. Medicina Clínica. 144(6). 247–253. 5 indexed citations

13.

Ancochea, Águeda, Alberto Álvarez‐Larrán, Cristian Morales‐Indiano, et al.. (2014). The role of serum erythropoietin level and jak2 v617f allele burden in the diagnosis of polycythaemia vera. British Journal of Haematology. 167(3). 411–417. 26 indexed citations

14.

Álvarez‐Larrán, Alberto, Luz Martínez‐Avilés, Juan Carlos Hernández‐Boluda, et al.. (2014). Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Annals of Hematology. 93(12). 2037–2043. 54 indexed citations

15.

Angona, Anna, Beatríz Bellosillo, Alberto Álvarez‐Larrán, et al.. (2013). Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide. Leukemia Research. 37(8). 917–921. 25 indexed citations

16.

Martínez‐Trillos, Alejandra, Margherita Maffioli, Dolors Colomer, et al.. (2013). Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. Annals of Hematology. 93(5). 797–802. 8 indexed citations

17.

Álvarez‐Larrán, Alberto, Anna Angona, Francesc García‐Pallarols, et al.. (2012). Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica. 97(11). 1704–1707. 40 indexed citations

18.

Martínez‐Avilés, Luz, Alberto Álvarez‐Larrán, Carles Besses, et al.. (2012). Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia. Annals of Hematology. 91(10). 1555–1562. 6 indexed citations

19.

Álvarez‐Larrán, Alberto, Anna Angona, Luz Martínez‐Avilés, Beatríz Bellosillo, & Carlos Besses. (2011). Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms. Leukemia Research. 36(3). 324–326. 12 indexed citations

20.

Hernández‐Boluda, Juan Carlos, Alberto Álvarez‐Larrán, Montse Gómez, et al.. (2010). Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. British Journal of Haematology. 152(1). 81–88. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact